126 related articles for article (PubMed ID: 20653479)
21. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
[TBL] [Abstract][Full Text] [Related]
22. Apparent central nervous system depression in infants after the use of topical brimonidine.
Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
[TBL] [Abstract][Full Text] [Related]
23. Formulation effects on ocular absorption of brimonidine in rabbit eyes.
Acheampong AA; Small D; Baumgarten V; Welty D; Tang-Liu D
J Ocul Pharmacol Ther; 2002 Aug; 18(4):325-37. PubMed ID: 12222763
[TBL] [Abstract][Full Text] [Related]
24. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
Lee DA; Gornbein J; Abrams C
J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
[TBL] [Abstract][Full Text] [Related]
25. Side-effect profile of brimonidine tartrate in children.
Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
[TBL] [Abstract][Full Text] [Related]
26. Vitreous concentration of topically applied brimonidine-purite 0.15%.
Kent AR; King L; Bartholomew LR
J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
Detry-Morel M; Dutrieux C
J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
29. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
Osborne SA; Montgomery DM; Morris D; McKay IC
Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
[TBL] [Abstract][Full Text] [Related]
30. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Williams GC; Orengo-Nania S; Gross RL
J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
[TBL] [Abstract][Full Text] [Related]
31. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
32. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
33. Brimonidine and pupillary diameter.
Mastropasqua L; Carpineto P; Ciancaglini M
Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
[No Abstract] [Full Text] [Related]
34. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
35. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
36. Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite.
Newman NJ; Biousse V; David R; Bhatti MT; Hamilton SR; Farris BK; Lesser RL; Newman SA; Turbin RE; Chen K; Keaney RP
Am J Ophthalmol; 2005 Sep; 140(3):407-15. PubMed ID: 16083844
[TBL] [Abstract][Full Text] [Related]
37. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
[TBL] [Abstract][Full Text] [Related]
38. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
39. Effect of 0.2% brimonidine on retinal blood flow.
Yu M; Li Y; Liu X; Ling Y; Zheng X
Yan Ke Xue Bao; 2001 Mar; 17(1):42-5. PubMed ID: 12567595
[TBL] [Abstract][Full Text] [Related]
40. Influence of topical brimonidine on visual field in glaucoma.
Ruiz Lapuente C; Ruiz Lapuente A; Link B
Eur J Ophthalmol; 2001; 11 Suppl 2():S67-71. PubMed ID: 11592534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
